Urologic Oncology
Biofabri S.L. is engaged in clinical research focused on high-risk non-muscle invasive bladder cancer, with particular interest in disease control after initial treatment.
- Bladder cancer
- Non-muscle invasive disease
- High-risk recurrence
The sponsor’s research activity centers on therapeutic strategies relevant to urothelial malignancy and bladder tumour management.
Oncologic Prevention
Its funded trial landscape includes prophylactic treatment approaches intended to reduce the likelihood of disease return in patients with non-muscle invasive bladder tumours.
- Recurrence prevention
- Adjuvant therapy
- Post-treatment disease control
These interests place emphasis on clinical strategies for maintaining remission in bladder cancer care.
Immunotherapy
The sponsor is involved in research related to BCG-based immunotherapy, reflecting interest in immune-directed approaches for bladder cancer management.
- Immune-based treatment
- Intravesical therapy
- Tumour immune response
Its clinical focus includes the use of biologic therapy in a urologic oncology setting.
Clinical Outcomes in Bladder Tumours
Research activity also addresses progression-free survival and other outcomes relevant to patients with high-risk NMIBT.
- Progression-free survival
- Tumour recurrence
- Risk-stratified bladder cancer care
This area reflects a therapeutic interest in measuring disease stability and long-term bladder cancer control.
